US 11,672,877 B2
In vivo immunoimaging of interferon-gamma
Nerissa Viola, Canton, MI (US); and Heather Gibson, Ferndale, MI (US)
Assigned to Wayne State University, Detroit, MI (US)
Appl. No. 16/640,456
Filed by Wayne State University, Detroit, MI (US)
PCT Filed Aug. 23, 2018, PCT No. PCT/US2018/047742
§ 371(c)(1), (2) Date Feb. 20, 2020,
PCT Pub. No. WO2019/040740, PCT Pub. Date Feb. 28, 2019.
Claims priority of provisional application 62/549,231, filed on Aug. 23, 2017.
Prior Publication US 2020/0206371 A1, Jul. 2, 2020
Int. Cl. A61K 51/10 (2006.01); C07K 16/24 (2006.01)
CPC A61K 51/1021 (2013.01) [A61K 51/1093 (2013.01); C07K 16/249 (2013.01)] 11 Claims
OG exemplary drawing
 
1. A method for in vivo immunoimaging interferon gamma (IFN-γ) as a marker of active T cells in a subject with cancer, comprising:
administering a labeled-antibody conjugate to a subject, wherein the labeled-antibody conjugate comprises:
an antibody that specifically binds to IFN-γ, and
a detection label conjugated to the antibody, wherein the detection label is a radionuclide tracer selected from 11C, 13N, 15O, 18F, 44Sc, 45Ti, 52Mn, 64Cu, 68Ga, 76Br, 82Rb, 86Y, 89Zr, 111In, 124I, 43K, 52Fe, 57Co, 67Cu, 67Ga, 77Br, 81Rb, 81mKr, 87mSr, 113mIn, 123I, 127Cs, 129Cs, 132I, 197Hg, 203Pb, 206Bi, or a combination of any two or more thereof; and
detecting the presence of the labeled-antibody conjugate in the subject in vivo by imaging, wherein specific binding of the labeled-antibody conjugate to IFN-γ indicates the presence of activated T cells.